Publications by authors named "Steve Swallow"

Claim this Profile
T
The impact of radiochemistry in drug projects: The use of C-14 label in the AZD8529, AZD7325, and AZD6280 projects.
Lee Kingston, Chungang Gu, Jian Guo, Steve Swallow, Charles S Elmore

J Labelled Comp Radiopharm· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC).
Richard A Ward, Mark J Anderton, Paul Bethel, Jason Breed, Calum Cook, Steve Swallow

J Med Chem· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point.
Richard A Ward, Paul Bethel, Calum Cook, Emma Davies, Judit E Debreczeni, Steve Swallow

J Med Chem· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986).
Kevin Doyle, Hans Lönn, Helena Käck, Amanda Van de Poël, Steve Swallow

J Med Chem· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aortic Binding of AZD5248: Mechanistic Insight and Reactivity Assays To Support Lead Optimzation.
Ryan A Bragg, Simon Brocklehurst, Frida Gustafsson, James Goodman, Kevin Hickling, Steve Swallow

Chem Res Toxicol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel and versatile synthesis of disubstituted 1,2-dihydro-1,2,4-triazol-3-ones.
Mark A Graham, Paul A Bethel, Jonathan Burgess, Gary Fairley, Steve C Glossop, Steve Swallow

Org Lett· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs.
Richard A Thompson, Emre M Isin, Yan Li, Lars Weidolf, Ken Page, Steve Swallow

Chem Res Toxicol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3(4H)-yl]benzamide (AZD6703), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases.
Dearg S Brown, John G Cumming, Paul Bethel, Jonathan Finlayson, Stefan Gerhardt, Steve Swallow

Bioorg Med Chem Lett· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules.
Tim Luker, Lilian Alcaraz, Kamaldeep K Chohan, Niklas Blomberg, Dearg S Brown, Steve Swallow

Bioorg Med Chem Lett· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fluorine in medicinal chemistry.
Sophie Purser, Peter R Moore, Steve Swallow, Véronique Gouverneur

Chem Soc Rev· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis